echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine's SHR8554-301 main research endpoint results meet the pre-specified superiority standard

    Hengrui Medicine's SHR8554-301 main research endpoint results meet the pre-specified superiority standard

    • Last Update: 2022-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 6, Hengrui Medicine issued an announcement stating that the main research endpoint of the Phase III clinical trial of SHR8554 injection (SHR8554-301) developed by the company and its subsidiaries Shanghai Hengrui Pharmaceutical Co.


    The SHR8554-301 study is a phase III clinical study evaluating the effectiveness and safety of SHR8554 injection for post-abdominal analgesia


    A total of 528 subjects were enrolled in this study.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.